Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0000921895-26-000365·Rein Therapeutics, Inc.
Schedule 13G ownership disclosure
REIN THERAPEUTICS INC
Common Stock, $0.001 par value · CUSIP: 00887A204
Event date: 2025-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Voss Value Master Fund, LP
Shares: 926,441.00 · Class: 3.5%
- Voss Value-Oriented Special Situations Fund, LP
Shares: 500,000.00 · Class: 1.9%
- Voss Advisors GP, LLC
Shares: 1,426,441.00 · Class: 5.4%
- Voss Capital, LP
Shares: 4,468,969.00 · Class: 17.0%
- Cocke Travis W.
Shares: 4,468,969.00 · Class: 17.0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000921895-26-000365
- Form type
- SCHEDULE 13G/A
- Filer
- Rein Therapeutics, Inc.
- CIK
- CIK 1420565
- Filed
- Feb 13, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership